Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
VTT, Dyadic to present data highlighting achievements in development of fungal production platform

VTT, Dyadic to present data highlighting achievements in development of fungal production platform

VTT and Dyadic International, Inc. (“Dyadic”) , today announced that VTT scientists will present the excellent results in their collaboration over the past two years at two international conferences: AAPS PharmSci on November 7th in Washington DC and PEGS Europe on November 14th in Lisbon.

The two-year research & development collaboration has successfully positioned Dyadic’s C1 Myceliophthora thermophila fungus as a potential production system for therapeutic proteins, vaccines and high value primary and secondary metabolites.

VTT and Dyadic will present data highlighting achievements reached to develop an extremely low protease and high producing platform strain that has resulted in the production of stable therapeutic antibodies with a final production rate of over 2.6 grams/litre/day. Furthermore, several difficult to express proteins, such as vaccine antigens and bispecific antibodies, have been produced at good levels in C1 as well as a specific primary metabolite through the metabolic engineering of C1. Additionally, specific information will be presented on the glycoengineering work to humanize the glycosylation machinery of C1 that has also generated promising results.

In addition, from the start of 2017 until now Dyadic and VTT have established research projects with ten third-parties including top pharmaceutical companies such as Mitsubishi Tanabe Pharma and Sanofi-Aventis. So far, research milestones were successfully achieved in all the completed projects.

“We are very excited about the impressive progress that was made by the VTT project team. I am sure that the high skills and experience of the VTT scientists in strain development will continue to help us to reach our ambitious goals of C1 to becoming an important production platform in the pharmaceutical world”, said Ronen Tchelet, Ph.D., VP Research and Business Development.

Dyadic’s industrially proven filamentous fungal strain of Myceliophthora thermophila nicknamed C1 is known as an extremely robust and efficient protein production organism in the enzyme industry. In addition to being able to produce high levels of proteins C1 produces glycan structures more similar to the human glycan forms than most other non-mammalian production hosts, making the glycoengineering work carried out in the project quicker and easier. Dyadic has developed and used its C1 production platform to produce industrial enzymes since the late 1990’s.

The pharma industry is producing therapeutic proteins mainly in the CHO (Chinese hamster ovary) cell system, but the current production processes are quite time consuming and expensive. In the Dyadic-VTT collaboration, rapid progress and significant advances have been made to the industrialized C1 host cell. This C1 gene expression platform provides the possibility to bring affordable medicines to patients sooner and at a lower cost while reducing the financial burden on the global healthcare system.

In the C1 development program, VTT is utilizing its strong competence in fungal molecular biology and bioprocesses that has been accumulated during more than 30 years of research on a variety of fungi. This collaboration has shown that the C1 system has excellent prospects for becoming a game changing platform for therapeutic protein production.

“The VTT project team is committed to making the production of new, better, lower cost medicines in C1 a reality in the future. We have been highly impressed with the great ability of the C1s fungus to produce proteins with high efficiency and good quality,” said Dr. Markku Saloheimo, Senior Principal Scientist at VTT.

Source:

https://www.vttresearch.com/media/news/vtt-and-dyadic-international-presenting-excellent-results-reached-in-development-of-a-new-fungal-production-platform-c1-for

Tagged with:

About author

Related Articles